Introduction
Forty thousand people die annually in the United Kingdom from lung cancer. Non-small cell lung cancer (NSCLC) forms the bulk (75%) of the disease.
Less than 20% ofpatients with NSCLC have an operable tumour at presentation and these patients have a five-year survival rate of only 30%. Patients with inoperable NSCLC have a median survival of [5] [6] months and despite radiotherapy treatment the five--year survival rate is only 3-10%'.
Chemotherapy for NSCLC in the past has been disappointing, with single-agent response rates reported from 3% to 40%2 and, in trials against single agents, combination chemotherapy producing up to a 39% response rate2'3.
Squamous cell carcinoma constitutes 400/0 of all lung cancer. Recently response rates of up to 75%, including 21% complete responses, have been reported using cisplatinum and bleomycin in combination in the treatmnent of squamous cell carcinoma of the bronchus4'6. We therefore decided to investigate the use and toxicity of a cisplatinum and bleomycin combination in a small study.
Patients and methods
Between May 1983 and October 1984, 13 consecutive patients with histologically verified squamous cell carcinoma of the bronchus were entered into a pilot study. All patients had advanced inoperable local disease but had not previously received radiotherapy or chemotherapy. The disease had to be measurable or evaluable and the patients had a life expectancy of at least 2 months, a performance status greater than 50 using the Karnofsky index, a white cell count in excess of 4000/ml, platelets greater than 100 000/ml and normal renal function.
Patients with severely reduced lung function, other major malignancy, coexistent serious somatic or psychological disease, previous radiotherapy or chemotherapy, or with a poor general condition were excluded from the study. Informed consent was obtained from all patients.
A full history and complete physical examination was performed on all patients, who also received the following investigations: full blood count, serum electrolytes, urea, creatinine, creatinine clearance, liver function tests, calcium, chest X-ray, bone scan, liver scan, bronchoscopy and biopsy. After completion of the investigations, staging according to the UICC TNM classification was carried out and the degree of differentiation in the histological specimens assessed where possible.
All patients received chemotherapy according to the following protocol: a 12-hour infusion of 2 litres of 5% dextrose 0.45% saline was followed by cisplatinum 20 mg/m2 in 500 ml of 5% dextrose 0.45% saline over 3 hours, followed by bleomycin 6mg/m2 in 2 litres of 5% dextrose 0.45% saline over 21 hours. This infusion schedule was repeated four times, resulting in a total of five days continuous infusion of alternating cisplatinum and bleomycin. During this time the patient also received prednisolone 1 mg/kg/day orally. The treatment course was repeated every 21 days for a total of up to four courses. Maintenance prednisolone 0.3mg/kg/day orally was administered between treatment courses. Dose reduction or delay, or treatment withdrawal, was carried out in cases of bone marrow suppression, reduced kidney function, reduced lung function or progressive disease. Assessments were completed on entry to the study and then prior to each course of chemotherapy and radiotherapy. Three weeks after completion of chemotherapy, radiotherapy was administered. Patients received 2000 cGy midline dose in five fractions over one week using opposed fields to the primary site and mediastinum either from 60 Co or a 5 MV linear accelerator. The course was repeated four weeks later using a three-field isocentric plan to reduce the dose to the spinal cord. Following completion of radiotherapy, patients were seen initially at six weeks and then at three-monthly intervals. Adequate treatment was defined as the completion of at least one course of chemotherapy and survival of at least three weeks from the start of treatment. Measurable disease was defined as that which could be measured on chest X-ray in two perpendicular diameters. Evaluable disease included lung or lobe collapse.
A complete response was defined as disappearance of all evidence of tumour for at least 4 weeks. A partial response was defined as more than a 50% reduction in the product of two perpendicular diameters of one or more measurable lesions or re-expansion of a previously collapsed lung or lobe of a lung with no new lesions appearing and no increase in other lesions, lasting at least four weeks. If there was less than a 50% reduction in size or progressive disease occurred, this was classified as no response. Survival was recorded from the first day of chemotherapy.
Results
A total of 13 patients were entered into this pilot study ( Table 1 and 2). All received at least 2 cycles of chemotherapy and 8 received the maximum of 4 cycles according to the protocol.
Six patients had a partial response. In 3 patients a collapsed lung lobe was fully re-expanded, in 2 an intrapulmonary metastasis disappeared with no increase in size of the primary, and in one patient there was a greater than 50% shrinkage of the primary lesion. There were no complete responders. Only one patient showed unequivocal evidence of progression, and 6 non-responders might have been classified as stationary disease. However, as these patients had large tumours, many would have died before a significant increase in size could have become apparent, and to classify the tumour as stationary when clinical progression and death occurs is misleading.
The median survival of all 13 patients was 5 months (Figure 1) . As in many studies, the responders survived longer than the non-responders with a median survival of 15 months compared to 3 months (Figure 2) . The non-responders contained more patients with known poor prognostic factors than the responders (Table 3) , with none of the 4 patients with a Karnofsky performance index of less than 80 responding, while 6/9 patients with a Karnofsky index greater or equal to 80 responded. Likewise 5/7 patients with a history of weight loss did not respond, while 4/6 patients with no weight loss did respond. Six of the non-responders did not complete the full course of chemotherapy and radiotherapy (Table 2) .
Toxicity was considerable (Table 4 ). Nausea and vomiting occurred in 10/13 patients and partial or complete alopecia occurred in all patients. Unusually, 2 patients developed the syndrome of inappropriate antidiuretic hormone (ADH) secretion with water overload. One became confused and subsequently died, the other developed generalized seizures but survived following treatment (see Appendix).
The longest surviving patient noticed markedly increased shortness of breath 10 months after commencing chemotherapy and 22 months after treatment he had become severely incapacitated by dyspnoea and required help with all daily activities (Karnofsky index -40). His chest X-ray showed marked mediastinal and pulmonary fibrosis ( Figure  3) . He died 26 months after entry into the study.
Discussion
A total of 13 patients were studied. No complete responses were observed, but 46% (6 patients) showed a partial response; 54% (7 patients) showed no response. The responders had a median survival of 15 months compared to only 3 months in the nonresponders. However, the median survival of the overall cohort was only 5 months, comparable to many published series'. Six of the 7 non-responders did not complete the full protocol although at least two courses of chemotherapy were administered to all patients. Since it would take five months to complete the full course of chemotherapy and radiotherapy it would be expected that unless a dramatic response was encountered, approximately half the patients would die before completing treatment, and this is what occurred. Nevertheless, it must be stressed that the intention was only to assess response to chemotherapy and toxicity, and it is implicit that to assess impact on survival a controlled trial is mandatory.
The toxicity of the regimen was considerable and much greater than alluded to in other studies68. Two patients developed the syndrome of inappropriate ADH secretion (SIADH), one at the end of the third and one at the end of the fourth course of chemotherapy. Despite intensive supportive measures, one patient died and was shown to have cerebral oedema at autopsy. SIADH has been reported both in association with squamous cell carcinoma of the bronchus9 and following treatment with cisplatinum1""'. We suspect the latter as the more likely cause, because both patients had completely normal electrolytes even at the start of the course of chemotherapy when the SIADH occurred.
Cerebral oedema might then easily be precipitated by the large fluid input required to maintain adequate hydration during platinum chemotherapy.
Although no pulmonary toxicity was observed during the course of treatment, the longest survivor in our series had marked mediastinal and pulmonary fibrosis with severe dyspnoea on minimal exertion and even at rest, and required help with all including the easiest of daily activities. We attribute this Figure 2 . Actualsurvivalofresponders versus non-responders receiving cisplatinum, bleomycin and radiotherapy for squamous carcinoma of the bronchus (O= responders, 0 = non-responders) Figure 3 . Chest X-ray showing severe mediastinal and pulmonary fibrosis secondary to chemotherapy with cisplatinum and bleomycin followed by radiotherapy to the mediastinum to tissue radiosensitization by bleomycin. Israel et al.6 reported that 17 of 367 patients developed acute pulmonary toxicity; 8 subsequently developed fibrosis and one died.
Our study confirms the fact that squamous cell carcinoma of the lung will definitely show a response to chemotherapy. This does not necessarily promise any improvement in survival. Israel et al.6 found the median survival in complete responders was 8.5 months, in partial responders 7 months and in non-responders only 5 months. Even without a control arm these results are disappointing. Itri et al.' found 5/14 partial responses in patients given cisplatinum, bleomycin and vindesine for squamous cell carcinoma. In their study, data for NSCLC were analysed together. The median survival for responding patients was 16 months versus 5 months for non-responders and they found that the addition of bleomycin to cisplatinum and vindesine7 did not appear to improve survival. Furthermore, the dangers of comparing responders to non-responders are well known3'12.
The place of chemotherapy remains unclear in the management ofsquamous carcinoma ofthe bronchus but current regimens do not dramatically prolong survival. Response rates alone do not necessarily promise any significant advantage to the patient and all future studies should contain a control arm. They should also contain details of the long-term effects of chemotherapy on the quality of life of longer-term surviving patients. Comment. This woman recovered with treatment. A brain scan was normal.
